Forskning ved Københavns Universitet - Københavns Universitet

Forside

Refining stability and dissolution rate of amorphous drug formulations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Refining stability and dissolution rate of amorphous drug formulations. / Grohganz, Holger; Priemel, Petra A; Löbmann, Korbinian; Nielsen, Line Hagner; Laitinen, Riikka; Mullertz, Anette; Van den Mooter, Guy; Rades, Thomas.

I: Expert Opinion on Drug Delivery, Bind 11, Nr. 6, 06.2014, s. 977-89.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Grohganz, H, Priemel, PA, Löbmann, K, Nielsen, LH, Laitinen, R, Mullertz, A, Van den Mooter, G & Rades, T 2014, 'Refining stability and dissolution rate of amorphous drug formulations', Expert Opinion on Drug Delivery, bind 11, nr. 6, s. 977-89. https://doi.org/10.1517/17425247.2014.911728

APA

Grohganz, H., Priemel, P. A., Löbmann, K., Nielsen, L. H., Laitinen, R., Mullertz, A., ... Rades, T. (2014). Refining stability and dissolution rate of amorphous drug formulations. Expert Opinion on Drug Delivery, 11(6), 977-89. https://doi.org/10.1517/17425247.2014.911728

Vancouver

Grohganz H, Priemel PA, Löbmann K, Nielsen LH, Laitinen R, Mullertz A o.a. Refining stability and dissolution rate of amorphous drug formulations. Expert Opinion on Drug Delivery. 2014 jun;11(6):977-89. https://doi.org/10.1517/17425247.2014.911728

Author

Grohganz, Holger ; Priemel, Petra A ; Löbmann, Korbinian ; Nielsen, Line Hagner ; Laitinen, Riikka ; Mullertz, Anette ; Van den Mooter, Guy ; Rades, Thomas. / Refining stability and dissolution rate of amorphous drug formulations. I: Expert Opinion on Drug Delivery. 2014 ; Bind 11, Nr. 6. s. 977-89.

Bibtex

@article{fb6709fa6ed9443daa43497750087950,
title = "Refining stability and dissolution rate of amorphous drug formulations",
abstract = "Introduction: Poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the main challenges in the development of new small molecular drugs. Additionally, the proportion of poorly soluble drugs among new chemical entities is increasing. The transfer of a crystalline drug to its amorphous counterpart is often seen as a potential solution to increase the solubility. However, amorphous systems are physically unstable. Therefore, pharmaceutical formulations scientists need to find ways to stabilise amorphous forms. Areas covered: The use of polymer-based solid dispersions is the most established technique for the stabilisation of amorphous forms, and this review will initially focus on new developments in this field. Additionally, newly discovered formulation approaches will be investigated, including approaches based on the physical restriction of crystallisation and crystal growth and on the interaction of APIs with small molecular compounds rather than polymers. Finally, in situ formation of an amorphous form might be an option to avoid storage problems altogether. Expert opinion: The diversity of poorly soluble APIs formulated in an amorphous drug delivery system will require different approaches for their stabilisation. Thus, increased focus on emerging techniques can be expected and a rational approach to decide the correct formulation is needed.",
author = "Holger Grohganz and Priemel, {Petra A} and Korbinian L{\"o}bmann and Nielsen, {Line Hagner} and Riikka Laitinen and Anette Mullertz and {Van den Mooter}, Guy and Thomas Rades",
year = "2014",
month = "6",
doi = "10.1517/17425247.2014.911728",
language = "English",
volume = "11",
pages = "977--89",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Refining stability and dissolution rate of amorphous drug formulations

AU - Grohganz, Holger

AU - Priemel, Petra A

AU - Löbmann, Korbinian

AU - Nielsen, Line Hagner

AU - Laitinen, Riikka

AU - Mullertz, Anette

AU - Van den Mooter, Guy

AU - Rades, Thomas

PY - 2014/6

Y1 - 2014/6

N2 - Introduction: Poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the main challenges in the development of new small molecular drugs. Additionally, the proportion of poorly soluble drugs among new chemical entities is increasing. The transfer of a crystalline drug to its amorphous counterpart is often seen as a potential solution to increase the solubility. However, amorphous systems are physically unstable. Therefore, pharmaceutical formulations scientists need to find ways to stabilise amorphous forms. Areas covered: The use of polymer-based solid dispersions is the most established technique for the stabilisation of amorphous forms, and this review will initially focus on new developments in this field. Additionally, newly discovered formulation approaches will be investigated, including approaches based on the physical restriction of crystallisation and crystal growth and on the interaction of APIs with small molecular compounds rather than polymers. Finally, in situ formation of an amorphous form might be an option to avoid storage problems altogether. Expert opinion: The diversity of poorly soluble APIs formulated in an amorphous drug delivery system will require different approaches for their stabilisation. Thus, increased focus on emerging techniques can be expected and a rational approach to decide the correct formulation is needed.

AB - Introduction: Poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the main challenges in the development of new small molecular drugs. Additionally, the proportion of poorly soluble drugs among new chemical entities is increasing. The transfer of a crystalline drug to its amorphous counterpart is often seen as a potential solution to increase the solubility. However, amorphous systems are physically unstable. Therefore, pharmaceutical formulations scientists need to find ways to stabilise amorphous forms. Areas covered: The use of polymer-based solid dispersions is the most established technique for the stabilisation of amorphous forms, and this review will initially focus on new developments in this field. Additionally, newly discovered formulation approaches will be investigated, including approaches based on the physical restriction of crystallisation and crystal growth and on the interaction of APIs with small molecular compounds rather than polymers. Finally, in situ formation of an amorphous form might be an option to avoid storage problems altogether. Expert opinion: The diversity of poorly soluble APIs formulated in an amorphous drug delivery system will require different approaches for their stabilisation. Thus, increased focus on emerging techniques can be expected and a rational approach to decide the correct formulation is needed.

U2 - 10.1517/17425247.2014.911728

DO - 10.1517/17425247.2014.911728

M3 - Journal article

C2 - 24754747

VL - 11

SP - 977

EP - 989

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 6

ER -

ID: 113037149